Hope is preparing for close-out meetings with the FDA. Chang said the team is “hopeful to advance to a phase 3 confirmatory trial” of the stem cell therapy candidate.

The FDA has authorized Mayo Clinic to offer mesenchymal stem cells as part of the Regenerative Nephrology Compassionate Use Program. This is an expanded access program.

A study published by In Vivo reports that cannabidiol (CBD) may help delay cellular aging in mesenchymal stem cells, ...

This therapy is one of a few drugs in mid-to-late-stage development for Parkinson’s that has displayed disease-modifying potential.

A Swedish startup aims to dominate stem cell production while nanotechnology is helping to transform cancer care. What does ...

Regulatory alignment supports rapid progress, tech transfer already underway to accelerate clinical readiness Company on ...

U.S. Patent No. 12,496,316, entitled “Treatment of Sexual Dysfunction and Improvement in Sexual Quality of Life,” provides Longeveron with patent rights in the United States through 2038. Further ...

Mechano-Growth Factor (MGF), often referred to as the IGF-1 Ec isoform (or IGF-1 Eb), is a splice variant of the insulin-like ...